Sign in

CIK 0001540159

  • Non-accelerated filer
  • Smaller reporting company

Edesa Biotech, Inc.

Sign in to watch
Ticker
EDSA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Sep 30
Incorporated
British Columbia, Canada
Entity type
Operating
Phone
+1 905-475-1234
Business address
C/O FASKEN MARTINEAU DUMOULIN LLP, 333 BAY STREET, SUITE 2400, TORONTO, Ontario, Canada, M5H 2T6
Former names
Stellar Biotechnologies, Inc.
  1. 4 Open-market buy Chief Executive Officer bought 5,000 shares at $1.92 ($9,599)
  2. 4 Open-market buy President bought 3,500 shares at $1.74 ($6,090)
  3. 4 Open-market buy Chief Executive Officer bought 2,000 shares at $1.80 ($3,600)
  4. 4 Open-market buy Chief Executive Officer bought 2,000 shares at $2.99 ($5,972)
  5. 4 Open-market buy Chief Executive Officer bought 2,000 shares at $3.05 ($6,098)
  6. 4 Derivatives Options or other derivatives
  7. 3 Insider Initial Statement of Ownership
  8. 4 Open-market buy Chief Executive Officer bought 2,000 shares at $3.02 ($6,034)
  9. 4 Open-market buy Chief Executive Officer bought 2,000 shares at $3.85 ($7,699)
  10. 4 Open-market buy Chief Executive Officer bought 2,000 shares at an average $3.26 ($6,522)
  11. 4 Open-market buy Chief Executive Officer bought 2,000 shares at $2.80 ($5,598)
  12. 4 Open-market buy President bought 1,250 shares at $2.79 ($3,487)
  13. 4 Open-market buy Chief Executive Officer bought 7,000 shares at an average $3.09 ($21,652)
  14. 4 Open-market buy President bought 1,000 shares at $3.22 ($3,223)
  15. 4 Open-market buy Chief Executive Officer bought 1,500 shares at $3.05 ($4,570)
  16. 4 Open-market buy President bought 1,250 shares at $2.90 ($3,622)
  17. 4 Derivatives Options or other derivatives
  18. 4 Derivatives Options or other derivatives
  19. 4 Derivatives Options or other derivatives
  20. 4 Derivatives Options or other derivatives

Page 6 of 14 · 261 filings